Cytosorbents (CTSO) Cash from Investing Activities Growth (1y) (2011 - 2026)
Powered by 
Analysis
Cytosorbents (CTSO) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | -15.64% |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | -110.20% |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | -125.17% |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | -514.42% |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | -73.71% |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | -12.26% |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | -44.16% |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 618.55% |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 0.00% |
| 10 | Cytosorbents | 20.00 Mn | 15.59 Mn | 7.05 Mn | 105.30% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 105.30% |
| Mar 31, 2026 | 2.13% |
| Dec 31, 2025 | -134.68% |
| Sep 30, 2025 | 118.39% |
| Jun 30, 2025 | -10.94% |
| Mar 31, 2025 | 63.00% |
| Dec 31, 2024 | 8.77% |
| Sep 30, 2024 | -16.02% |
| Jun 30, 2024 | -184.81% |
| Mar 31, 2024 | 81.40% |
| Dec 31, 2023 | 34.04% |
| Sep 30, 2023 | 64.03% |
| Jun 30, 2023 | 102.99% |
| Mar 31, 2023 | 19.47% |
| Dec 31, 2022 | 87.68% |
| Sep 30, 2022 | 29.58% |
| Jun 30, 2022 | -375.79% |
| Mar 31, 2022 | -39.85% |
| Dec 31, 2021 | -528.53% |
| Sep 30, 2021 | -151.75% |